

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 62978

Title: Thymosin as a possible therapeutic drug for COVID-19: A case report

Reviewer's code: 03262105

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Turkey

Author's Country/Territory: China

Manuscript submission date: 2021-01-22

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-01-25 12:25

Reviewer performed review: 2021-01-25 12:36

Review time: 1 Hour

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

Interesting case report about COVID-19 treatment
how , IM?

Please include injection type: IV?

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 62978

Title: Thymosin as a possible therapeutic drug for COVID-19: A case report

Reviewer's code: 05849037

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Iran

Author's Country/Territory: China

Manuscript submission date: 2021-01-22

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-02-23 05:12

Reviewer performed review: 2021-02-27 09:10

Review time: 4 Days and 3 Hours

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

In the present case, authors have introduced Thymosin as a possible therapeutic drug for COVID-19. I have several comments. In case presentation section: Please explain the contents continuously, not separately. Please remove Table 1, and write data in text. Some data summarized in Table1 is repeated in text. It is better you write all patient information and result in text. This sentence: "Considering that the patient had a history of contact with a confirmed COVID-19 patient in Russia, the most likely infection was by SARS-CoV-2". You cannot decide on the probability unless the patient has strong clinical symptoms or a positive COVID-19 laboratory test. Which commercial kit was used to detect antibodies? Please indicate the dose of medication. Based on what evidence do you claim that thymosin is involved in the treatment of the disease? In figure 1: please add arrows to the figure according to findings.